报价延迟最少15分钟:2026/04/15 11:57 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.0002 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.04/-1.09
|
|
企业价值
263.48M
|
| 资产负债 |
|
每股账面净值
3.29
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
40.37M
|
|
每股收益
2.66
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associatedvirus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous,or IV, dosing. Its segment is developing and commercializing genetic medicine. |
